Is Inavolisib included in the scope of medical insurance reimbursement?

Inavolisib (Inavolisib), as a new generation of PI3Kα inhibitor, has been launched in China, but it is not yet included in the medical insurance coverage. Common specifications include 3mg 7 tablets for 4 boards and 9mg 7 tablets for 4 boards. Due to the short time the drug has been on the market, its domestic pricing and actual payment amount are not yet fully clear. In overseas markets, inarisep is also used as an innovative targeted drug for the treatment of HR-positive, HER2-negative, and PIK3CA-mutated breast cancer. Although the efficacy is clear, high drug prices and gaps in medical insurance coverage put financial burden on patients.

When domestic patients use inaliset, they need to weigh it based on their own economic conditions and clinical needs. Some medical institutions and pharmaceutical companies may offer special medication assistance programs to help patients access treatment. At the same time, as the time to market of drugs extends and clinical application data accumulates, there is room for improvement in the possibility of entering medical insurance in the future. Once included in medical insurance, it is expected to significantly reduce patient burden, expand treatment coverage, and enable more patients with HR-positive, PIK3CA-mutated locally advanced or metastatic breast cancer to receive standardized and continuous treatment.

During treatment with inalise, patients should understand the drug supply and purchase channels in advance to ensure continuity of medication. The physician team will provide personalized medication plans based on the patient's tumor characteristics, previous treatment history, and financial status, and rationally arrange combined treatments and follow-up evaluations to optimize efficacy and safety. In summary, although inarisep has not yet been included in domestic medical insurance, its clinical value as a precision-targeted drug has been recognized, providing a new treatment option for patients with endocrine-resistant breast cancer, and is expected to improve accessibility with policy adjustments.

Reference materials:https://www.itovebi-hcp.com/